Receptor, ErbB-2 Concept

subject area of

• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer  Academic Article
• HER2and Responsiveness of Breast Cancer to Adjuvant Chemotherapy  Academic Article
• neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II  Academic Article
• A Novel Approach to Tumor Suppression with Microencapsulated Recombinant Cells  Academic Article
• A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer  Academic Article
• A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features  Academic Article
• A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial  Academic Article
• A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.  Academic Article
• Activity of fulvestrant in HER2-overexpressing advanced breast cancer  Academic Article
• Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients  Academic Article
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer  Academic Article
• Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial  Academic Article
• Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial  Academic Article
• Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review  Academic Article
• Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes  Academic Article
• An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction  Academic Article
• Anthracyclines in Early Breast Cancer  Academic Article
• Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?  Academic Article
• Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer  Academic Article
• Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients  Academic Article
• Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer  Academic Article
• BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays  Academic Article
• Black Cohosh Increases Metastatic Mammary Cancer in Transgenic Mice Expressing c-erbB2  Academic Article
• Blood HER2 and Uromodulin as Causal Mediators of CKD  Academic Article
• Breast cancer risk factors and HER2 over-expression in tumors.  Academic Article
• Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer  Academic Article
• Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.  Conference Paper
• Characterizing Complex Polysera Produced by Antigen-Specific Immunization through the Use of Affinity-Selected Mimotopes  Academic Article
• Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial  Academic Article
• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer  Academic Article
• Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy  Academic Article
• Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial  Academic Article
• Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer  Academic Article
• Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?  Academic Article
• Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2  Academic Article
• Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression  Academic Article
• Developmental and Lactational Exposure to Dieldrin Alters Mammary Tumorigenesis in Her2/neu Transgenic Mice  Academic Article
• Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer  Academic Article
• Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow Biopsies  Academic Article
• Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones  Academic Article
• Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer  Academic Article
• Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study  Academic Article
• Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators  Academic Article
• Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial  Academic Article
• Endocrine therapy: is the first generation of targeted drugs the last?  Academic Article
• Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor  Academic Article
• Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer  Academic Article
• Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression  Academic Article
• Epirubicin in Breast Cancer: Present and Future  Academic Article
• ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors  Conference Paper
• ErbB2 IS A TUMOR ASSOCIATED ANTIGEN AND A SUITABLE THERAPEUTIC TARGET IN WILMS TUMOR  Academic Article
• ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival  Academic Article
• ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis  Academic Article
• Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours  Academic Article
• Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer  Academic Article
• Expression of EGFR, HER-2/neu and KIT in germ cell tumours  Academic Article
• Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence  Academic Article
• Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease  Academic Article
• Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab  Academic Article
• First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients  Academic Article
• Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib  Academic Article
• Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model  Academic Article
• HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab  Academic Article
• HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data  Academic Article
• HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer  Academic Article
• Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer  Academic Article
• Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2⁻advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy  Academic Article
• Herceptest: Her2 expression and gene amplification in non-small cell lung cancer  Academic Article
• Hormone Receptor and ERBB2 Status in Gene Expression Profiles of Human Breast Tumor Samples  Academic Article
• INHIBITION OF WILMS TUMOR XENOGRAFT PROGRESSION BY HALOFUGINONE IS ACCOMPANIED BY ACTIVATION OF WT-1 GENE EXPRESSION  Conference Paper
• Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy  Academic Article
• Identification of a Novel Luminal Molecular Subtype of Breast Cancer  Academic Article
• Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy  Academic Article
• Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.  Academic Article
• Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators  Academic Article
• Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy  Academic Article
• Impaired c-src activation and motility defects in PEA3-null fibroblasts  Academic Article
• Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12  Academic Article
• Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2  Academic Article
• Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival  Academic Article
• Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth  Academic Article
• Invasive lobular carcinoma: to grade or not to grade  Academic Article
• Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31  Academic Article
• Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial  Academic Article
• Locally advanced breast cancer in octogenarian women  Academic Article
• Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy  Academic Article
• Loss of Antigenicity in Stored Sections of Breast Cancer Tissue Microarrays  Academic Article
• Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009  Academic Article
• Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial  Academic Article
• Mesenchymal Stromal Cells Expressing ErbB-2/neu Elicit Protective Antibreast Tumor Immunity In vivo, Which Is Paradoxically Suppressed by IFN-γ and Tumor Necrosis Factor-α Priming  Academic Article
• Micronutrients Involved in One-Carbon Metabolism and Risk of Breast Cancer Subtypes  Academic Article
• Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set  Academic Article
• Novel method for differentiation between Trastuzumab and host adaptive response  Academic Article
• Nuclear Kaiso Expression Is Associated with High Grade and Triple-Negative Invasive Breast Cancer  Academic Article
• Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research  Academic Article
• Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4  Academic Article
• Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial  Conference Paper
• Performance of preoperative breast MRI based on breast cancer molecular subtype  Academic Article
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013  Academic Article
• Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women  Academic Article
• Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer Cells  Academic Article
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker  Academic Article
• Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor–Positive Breast Cancer  Conference Paper
• Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer  Academic Article
• Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario  Academic Article
• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer  Academic Article
• Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial  Academic Article
• Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative  Academic Article
• Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia  Academic Article
• Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14  Academic Article
• Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis  Academic Article
• Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial  Academic Article
• Role of Ets transcription factors in mammary gland development and oncogenesis.  Academic Article
• Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2  Academic Article
• Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression  Academic Article
• Salad vegetables dietary pattern protects against HER-2-positive breast cancer: A prospective Italian study  Academic Article
• Scavenging of Extracellular H2O2 by Catalase Inhibits the Proliferation of HER-2/Neu-transformed Rat-1 Fibroblasts through the Induction of a Stress Response  Academic Article
• Secretory Breast Carcinoma: Unique, Triple-Negative Carcinoma With a Favorable Prognosis and Characteristic Molecular Expression  Academic Article
• Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort  Academic Article
• Small Molecule Antagonists of the Wnt/Beta-Catenin Signaling Pathway Target Breast Tumor-Initiating Cells in a Her2/Neu Mouse Model of Breast Cancer  Academic Article
• TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients  Academic Article
• Tailored targeted therapy for all: a realistic and worthwhile objective against  Academic Article
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015  Academic Article
• The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32  Academic Article
• The HER-2/neu oncogene in breast cancer: so what is new?  Academic Article
• The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase  Academic Article
• The Role of HER-2/neu Oncogene and Vimentin Filaments in the Production of the Paget's Phenotype  Academic Article
• The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity  Academic Article
• The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures  Academic Article
• The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis  Academic Article
• The role of circulating extracellular vesicles in breast cancer classification and molecular subtyping  Academic Article
• Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications  Academic Article
• Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial  Academic Article
• Trastuzumab Cardiac Side Effects: Only Time Will Tell  Academic Article
• Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study  Academic Article
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials  Academic Article
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial  Academic Article
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence  Academic Article
• Tumor Protection Following Vaccination With Low Doses of Lentivirally Transduced DCs Expressing the Self-antigen erbB2  Academic Article
• Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?  Academic Article